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http://www.biomedcentral.com/1472-6963/14/611RESEARCH ARTICLE Open AccessUsing a discrete choice experiment to inform the
design of programs to promote colon cancer
screening for vulnerable populations in
North Carolina
Michael P Pignone1*, Trisha M Crutchfield2, Paul M Brown3, Sarah T Hawley4, Jane L Laping5, Carmen L Lewis6,
Kristen Hassmiller Lich7, Lisa C Richardson8, Florence KL Tangka8 and Stephanie B Wheeler7Abstract
Background: Screening for colorectal cancer (CRC) is suboptimal, particularly for vulnerable populations. Effective
intervention programs are needed to increase screening rates. We used a discrete choice experiment (DCE) to learn
about how vulnerable individuals in North Carolina value different aspects of CRC screening programs.
Methods: We enrolled English-speaking adults ages 50–75 at average risk of CRC from rural North Carolina communities
with low rates of CRC screening, targeting those with public or no insurance and low incomes. Participants received
basic information about CRC screening and potential program features, then completed a 16 task DCE and survey
questions that examined preferences for four attributes of screening programs: testing options available; travel time
required; money paid for screening or rewards for completing screening; and the portion of the cost of follow-up care
paid out of pocket. We used Hierarchical Bayesian methods to calculate individual-level utilities for the 4 attributes’
levels and individual-level attribute importance scores. For each individual, the attribute with the highest importance
score was considered the most important attribute. Individual utilities were then aggregated to produce mean utilities
for each attribute. We also compared DCE-based results with those from direct questions in a post-DCE survey.
Results: We enrolled 150 adults. Mean age was 57.8 (range 50–74); 55% were women; 76% White and 19%
African-American; 87% annual household income under $30,000; and 51% were uninsured. Individuals preferred shorter
travel; rewards or small copayments compared with large copayments; programs that included stool testing as an
option; and greater coverage of follow-up costs. Follow-up cost coverage was most frequently found to be the most
important attribute from the DCE (47%); followed by test reward/copayment (33%). From the survey, proportion of
follow-up costs paid was most frequently cited as most important (42% of participants), followed by testing options
(32%). There was moderate agreement (45%) in attribute importance between the DCE and the single question in the
post-DCE survey.
Conclusions: Screening test copayments and follow-up care coverage costs are important program characteristics in
this vulnerable, rural population.
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Screening reduces colorectal cancer (CRC) incidence
and mortality, and is cost-effective [1,2]. Unfortunately,
CRC screening is underutilized, particularly in vulner-
able populations, defined as those with low incomes, in-
adequate or no health insurance, or those who live far
from health care facilities [3-6]. Data from national sur-
veys suggest that over a third of US adults ages 50–75
are not up to date with CRC screening; levels are even
lower for vulnerable populations: for example, fewer
than 50% of those with no insurance report being up to
date with CRC screening [6].
The US government’s Healthy People 2020 goals set a
target of having 70.5% of eligible adults up to date with
CRC screening by 2020 [7]. Effective programs to reach
vulnerable populations (and increase their rates of CRC
screening) are essential to bring the benefits of CRC
screening to the full US population and reach national
objectives. Increasing CRC screening is also an impor-
tant part of payer-based healthcare quality improvement
and pay for performance efforts.
Several types of interventions, including small media,
patient and provider reminders, and possibly financial
incentives are effective in increasing screening, and some
of these interventions have been tested in vulnerable
populations [8]. However, these effective interventions
have not been widely disseminated [6]. Reasons for fail-
ure of dissemination may include intervention com-
plexity, costs of intervention, challenges in scaling, or
difficulty in choosing among potentially effective inter-
ventions. Policy makers and payers may need to decide
among potential options for programs to increase CRC
screening among vulnerable populations, including the
option of maintaining the status quo.
For a screening program to be effective, it must be ac-
ceptable to the targeted population, easily accessible, and
readily available at an acceptable price. Information on the
public's preferences between types of screening programs
will aid policy makers in designing, implementing and dis-
seminating effective programs. One method for informing
decisions about potential options for increasing CRC
screening among vulnerable populations is to elicit feed-
back from members of vulnerable groups about the fea-
tures of potential programs.
Discrete choice experiment (DCE) is one potentially
valuable method for eliciting such feedback. DCE pre-
supposes that a “product” like a screening promotion
program can be described in terms of its features or “at-
tributes” and that by understanding the different features
and how people value them, effective programs can be
designed and implemented to address the needs of the
population [9]. Although stated preference methods, in-
cluding DCE, have been used to understand patient pre-
ferences for different CRC screening tests [10-12], to ourknowledge, DCE has not been used in the design of pro-
grams to increase CRC screening among vulnerable popu-
lations in the US, such as those with low income or those
who are under- or uninsured. As such, we designed and
performed a DCE among members of vulnerable popula-
tions in North Carolina to provide information to assist
policymakers in the design and implementation of pro-
grams to promote CRC screening.
Methods
Overview
We identified rural North Carolina counties with low
CRC screening rates and elevated CRC mortality by lin-
king North Carolina Cancer registry data to Medicare
and Medicaid claims data using demonstrated methods
[13,14]. Three counties in western North Carolina were
selected for further study. We then recruited and sur-
veyed English-speaking, adults ages 50–75 at average
risk for CRC about their preferences and values regar-
ding possible CRC screening programs.
Ethical considerations
This study was approved by the Institutional Review
Board at the University of North Carolina at Chapel Hill.
Survey content
The study team designed a paper-based survey based on
our prior research [10,11], existing literature [15-19], and
pre-testing feedback (See Additional file 1). The survey
began with general information about colon cancer and
features of colon cancer screening programs and asked
participants to complete a DCE, a rating task and several
additional questions. We used the term “colon cancer”
rather than “colorectal cancer” to ensure understanding
among the target population.
Discrete choice experiments
In a DCE, individuals are asked to choose between hypo-
thetical alternatives described by a set of attributes and
levels. The levels of the attributes are varied systematically
in a series of choice tasks where participants are asked to
select an option that they most prefer. Responses to the
choices are modeled to provide quantitative information
about the relative value participants attach to different
levels of the attributes being considered [20].
Selection of key attributes and levels
We developed four key attributes of CRC screening pro-
grams from the literature and prior research, which include,
testing options, travel time, money paid for screening, and
the portion of the cost of follow-up care paid out of
pocket [10,11,16-19].
We developed a plausible range of levels for each attri-
bute. We framed the testing options attribute by employing
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copy only) and two options with a choice (choice of stool
test or colonoscopy; choice of stool test, colonoscopy, or
CT colonography).We did not include sigmoidoscopy as
one of the testing options within a program because our
formative research suggested it was not readily available in
the study area.
Travel time options ranging from “no travel” to
“1 hour + .” were based on distances to nearest endos-
copy facilities from our formative work [13]. These times
are suitable for the rural geographic region where the
study occurred and allowed individuals who may have
difficulty conceptualizing distance (e.g. individuals who
do not drive) to state their preference.
Money paid for screening was framed to include re-
wards and costs (copayments) within the same attribute,
ranging from a $100 reward to a $1000 cost, with the
highest amount of cost designed to simulate the cost of
colonoscopy screening without insurance coverage. [21].
We represented out-of-pocket follow-up costs using
percentages rather than absolute costs because it is im-
possible to know what the out-of-pocket follow-up costs
might be with the selection of any given screening test.
The outcome of the initial screening test and subsequent
testing or treatment utilized, factor into the total out-of-
pocket costs, and will differ for each individual. Given
the uncertainty and difficulty in making a choice among
these levels, we decided to frame the levels in a way that
is likely to be familiar to individuals - as insurance
coverage. The levels ranged from no coverage (100%
paid by the person) to a 20% copayment, to full coverage
(0% out of pocket expense).
Development of the DCE
We used Sawtooth Software Version 8 to design a ba-
lanced and efficient set of 16 choice tasks (with 1 domi-
nant task): this number of questions has been shown inFigure 1 An example discrete choice experiment task.past work to be feasible for participants to complete
[10,11]. Each choice was comprised of two active scree-
ning options and a fixed “opt-out” option (“Given these
options, I would not get screened”). A sample choice task
is included in Figure 1. Our study followed the Inter-
national Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Guidelines [22] for DCE design.
Post-DCE questions
Following the DCE, participants completed a rating task
where they were asked to rate screening program attri-
butes (on a scale from 0, meaning not important at all, to
5, very important, which were converted to a 1 to 6 scale
for analysis). Participants were then asked to answer
which single program attribute was most important- we
called this the “directly selected most important attribute”.
Pretesting
The survey was pre-tested with 53 individuals in 6
gender-stratified focus groups held in 2 eastern North
Carolina counties and 3 western North Carolina coun-
ties, from March 28, 2012 to September 7, 2012. Based
on participant feedback, the survey was modified to in-
clude a table of pictograms comparing CRC screening op-
tions, and bulleted, condensed text to improve readability
and comprehension. The table of pictograms illustrating
screening test options was drawn from evidence-based
materials from the National Cancer Institute (http://
gutcheck.cancer.gov/screenings/index.html) and from clip
art (See Additional file 1).
Data collection
Participants were recruited from community-based orga-
nizations in the region from October 23, 2012 to March
23, 2013. Eligibility criteria included residing in the area
of interest (in an identified county or in an adjacent
county), being 50 – 75 years of age, having average risk
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no history of inflammatory bowel disease), having a life
expectancy of 2+ years, and being able to read English.
Participants were identified and screened for eligibility
by one of two methods. Most commonly, individuals
learned of the study and called a dedicated phone num-
ber, were screened by study personnel, and scheduled an
appointment to be surveyed at survey sites, including
flea markets, senior centers, discount stores, public
housing authorities and medical clinics. Additionally,
participants were recruited in-person at survey sites and
were screened and administered surveys on a walk-in
basis.
To ensure sufficient representation of vulnerable popu-
lations within the sample, the study team adopted a pur-
poseful sampling approach for recruitment. We sought to
enroll uninsured individuals (at least 50%) or publicly in-
sured individuals (Medicare, Medicaid, Veterans benefits);
individuals who were not up-to-date with screening (col-
onoscopy more than 10 years ago, sigmoidoscopy more
than 5 years ago, Fecal Occult Blood Test (FOBT) or Fecal
Immunochemical Test (FIT) more than one year ago);
individuals who have a low annual household income
(< $45,000); and minority groups (African-American and
Hispanic participants).
Participants provided consent and were asked to take
the survey in semi-private areas. The survey was admi-
nistered on paper. Each individual was given the option
of having the entire survey read aloud by a study team
member. Study team members carefully explained how
to complete the survey and took the time to explain the
DCE process, and went through a practice DCE task to
help reduce concerns and uncertainties about how to
answer DCE questions. Upon completion of the survey,
participants received a $35 gift card.
Study outcomes
The primary outcomes of interest were the mean utility
levels for the four attributes, and the DCE-calculated most
important attributes for each individual, based on their
individual utility levels. Secondary outcomes of interest
include the directly reported single most important attri-
bute and the agreement between the DCE-generated and
directly selected most important attribute.
Sample size determination
Because there is no optimal method for determining the
sample size for DCE, we used the method suggested by
Johnson to determine that a sample size of 150 partici-
pants would yield reasonably precise estimates of utility
levels, given the use of 16 choice tasks, two active alter-
natives, and a maximum number of levels within a single
attribute of six [23]. We continued recruitment until we
reached this goal.Statistical analysis
We performed descriptive analyses with means and pro-
portions using Stata version 12.
The DCE survey responses were analyzed using
Choice Based Conjoint (CBC) Hierarchical Bayesian
(HB) module in Sawtooth Software to obtain individual-
level preferences. The CBC/HB module uses data from
the DCE in a mixed effects multivariate, multinomial
logit model to estimate the value or “utility” each par-
ticipant attaches to the different levels of the 4 attri-
butes. The value associated with the “opt-out” choice is
expressed as a constant [24].
The Hierarchical Bayesian process used in Sawtooth
Software is a two-step process to determine individual-
level utilities. First, average utilities are calculated for the
full sample of participants, and how much each indivi-
dual’s responses differ from the average. Secondly, indi-
vidual utilities are adjusted to an optimal mix of average
sample utilities and individual utilities, based on the
amount of information provided by participants and the
variance in the sample average (Markov Chain Monte
Carlo). These individual-level utility estimates are then
averaged to give the population mean utilities [24].
Utilities are arbitrarily-scaled, zero-centered values
that represent the relative desirability of the levels within
each attribute in numerical form: the higher the number
the more desirable it is to participants and conversely,
the lower (more negative) the number, the less desirable
it is to participants [20]. Each participant’s utilities are
then used to calculate individual-level attribute impor-
tance scores. Attribute importance scores represent the
relative importance of the four attributes, given the
range of levels employed [20]. Attribute importance
scores were calculated for each individual separately and
then averaged for mean importance scores.
For each individual, the attribute with the highest im-
portance score from the DCE is considered to be “most
important” for that individual. We compared the DCE-
based most important attribute with the most important
attribute based on a single post-DCE survey question to
determine if they represented different information.
Results
There were 360 individuals who expressed interest in
the study and 175 potential participants were found
eligible. Twenty-four participants declined participation,
1 did not complete, and 150 individuals completed the
survey (85.7%).
Participant characteristics are shown in Table 1. Mean
age was 58 years, and 55% were female. Most (76%) were
White and 40% had a high school education or less. Par-
ticipants had low household incomes (87% reported less
than $30,000 per year) and 51% were uninsured. Most
(76%) had never been screened for CRC.
Table 1 Vulnerable North Carolinians completing CRC
screening preference questionnaire (n = 150)
Mean age (SD) 57.9 (6.2)
Gender
Female 55.3%
Race/Ethnicity
White 76.0%
African American 19.3%
Hispanic/Latino 2.0%
Other 2.7%
Education
Less than high school graduate 10.7%
High school graduate/GED 29.5%
Some College OR 2-year college Graduate 36.5%
4 Year College graduate or more 23.5%
Need help with written materials
Always 2.0%
Often 2.0%
Sometimes 13.3%
Rarely 24.0%
Never 58.7%
Income
<$30,000 87.4%
$30,000-59,999 12.6%
Employment
Employed 28.2%
Retired 19.5%
Unemployed 21.5%
Disabled 24.2%
Other 6.7%
CRC screening status
Never Screened 76.0%
Ever Screened, Not Up to date 21.3%
Up to Date 2.7%
Insurance Statusa
Uninsured 50.7%
Private Insurance 7.4%
Medicaid 20.9%
Medicare 31.3%
Medicare Supplement 8.1%
VA/Military Benefits 5.4%
Abbreviations: CRC Colorectal Cancer, SD Standard Deviation, GED General
Educational Development, VA Veterans Affairs.
aInsurance Status categories may overlap, as some individuals are insured by
multiple policies or programs.
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constant associated with “Given these options, I would
not get screened” suggests a strong overall preference
for participation in CRC screening programs. Over 80%
of respondents answered the dominant question cor-
rectly, suggesting good understanding and engagement
in the survey.
As predicted, participants preferred no or shorter travel
times compared with longer travel times. They also exhib-
ited strong preferences for the larger ($100) reward for
screening and against the highest screening test copay-
ment of $1000. Interestingly, they had few differences in
utility among small ($10) rewards, small-moderate copay-
ments ($25- $100), or the lack of a reward or copayment.
These findings suggest that individuals would be more
likely to be screened if given a large reward (small rewards
and copayments are less likely to have a significant im-
pact) and would be discouraged from participating in a
program where they had to bear large costs for screening.
The proportion of follow-up costs covered by the
screening program was also important: participants
strongly preferred full or nearly full coverage of follow-
up costs compared with programs in which they would
be responsible for 50 or 100% of these costs.
Utility levels for test choices available within the hy-
pothetical screening programs had a less consistent pat-
tern. In general, participants appeared to value having
the option of stool test screening, whether as the only
testing option or as part of a suite of options that in-
cluded CT colonography and colonoscopy. In contrast,
programs offering colonoscopy as the only option or
offering a choice of stool test or colonoscopy were rela-
tively less popular.
Mean attribute importance scores, which reflect the
relative importance of the four attributes compared to
one another, given the levels of the attributes employed,
suggested that the cost variables were relatively more
important than testing options or travel time: follow-up
care cost had a 34% importance score, followed by
money paid for screening (reward or copayment) at 33%.
The other attributes, testing options (17%) and travel
time (16%), were somewhat less important given the
ranges of levels tested.
Post-DCE survey
In the post-DCE survey, participants’ ratings of the im-
portance of the attributes had some similarities to the
DCE results: the cost of follow-up care was rated to be
very important (mean 5.5, SD 1.1 on a 1–6 scale), while
travel time was rated to be of lower importance (mean
3.4, SD 1.8). In contrast, testing options were considered
to be quite important (mean 5.3, SD 1.2), and out of
pocket costs or rewards somewhat less so (mean 4.6,
SD 1.8).
Table 2 Discrete choice experiment results: colorectal cancer screening program preferences among vulnerable North
Carolinians
Attribute Level Meana
raw utilities
Lower CI Upper CI Mean attributeb Importance
scores (CI)
Testing options Stool test only 0.60 0.33 0.87 0.17 (0.16 - 0.18)
Colonoscopy only −0.42 −0.72 −0.12
Choice: stool test OR Colonoscopy −0.61 −0.76 −0.47
Choice: stool test, Colonoscopy OR CT
Colonography
0.43 0.26 0.60
Travel time No Travel 1.03 0.89 1.17 0.16 (0.15 - 0.17)
15 minutes 0.92 0.78 1.06
30 minutes 0.32 0.23 0.41
45 minutes −0.96 −1.15 −0.77
1 hour + −1.31 −1.46 −1.16
Money paid for
screening
$100 Reward 2.50 2.24 2.75 0.33 (0.32 - 0.35)
$10 Reward −0.06 −0.23 0.10
$0 0.30 0.06 0.53
$25 Cost 1.08 0.87 1.29
$100 Cost −0.15 −0.41 0.11
$1000 Cost −3.66 −3.96 −3.36
% follow-up care cost
you pay
0% 2.79 2.33 3.25 0.34 (0.32 - 0.36)
5% 1.68 1.40 1.96
20% 0.42 0.30 0.55
50% −1.48 −1.73 −1.23
100% −3.42 −3.84 −2.99
None Given these options, I would not get screened −3.19 −3.82 −2.56 n/a
Abbreviations: CI Confidence Interval, CT Computerized Tomography.
aMean raw utilities indicate the relative desirability of each level within an attribute; the higher the number, the more desirable; the lower the number (the more
negative), the less desirable.
bThe relative importance of each attribute, when the stated levels included are employed. The importance scores sum to 1.0 and can be interpreted as proportions.
Table 3 Agreement between most importance attribute
and most important single question attribute
Counts of question responsesa
DCE most important attribute
Testing
options
Travel
time
Screening
rewards/Costs
Follow-up
costs
Totals
Single question
most important
attribute
Testing Options 9 0 24 15 48
Travel Time 0 0 1 1 2
Screening
Rewards/Costs
1 1 17 16 35
Follow-up Costs 2 0 21 40 63
Totals 12 1 63 72 148
Abbreviation: DCE Discrete Choice Experiment.
aAgreement 66/148 (45%), determined by taking a count of the questions
that were answered the same (as indicated by the bold numbers in the
diagonal- 66 total) and dividing by the total number of responses (148).
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tion, was most frequently found to be the costs of
follow-up care (42%), followed by testing options (32%),
and out of pocket screening test costs or rewards (23%).
Only 1.3% of participants considered travel time to be
most important.
Agreement between DCE and survey results
Table 3 shows the agreement between participants’ most
important attribute as calculated from the DCE in com-
parison with their responses to the single question from
the post-DCE survey. Overall, 66 of 148 (45%) parti-
cipants had agreement between these two methods for
assessing attribute importance, with most differences
coming from differences between methods in the value
attributed to testing options compared with costs.
Discussion
In our survey of vulnerable adults in North Carolina, we
found strong overall interest in programs to promote
CRC screening. Program costs, both those associated
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initial screening, strongly influenced participants’ pre-
ferences. Participants’ responses also seemed to favor
programs that included the option of stool testing, which
may also reflect concerns about the costs of scree-
ning colonoscopy. Somewhat surprisingly, travel time
appeared relatively much less important, perhaps reflec-
ting the rural setting for our survey; residents of rural
areas may be more accustomed to traveling relatively
long distances and times to obtain health care, and
hence attribute less relative importance to it.
Our study is the first, to our knowledge, to use DCE to
examine features of potential CRC screening programs in
the United States (US). Our findings have several potential
implications for US health policy and for future research.
First, they suggest that in order to maximize uptake and
effectiveness, policymakers could encourage the develop-
ment of programs that account for both initial screening
costs and subsequent costs for additional testing (e.g. diag-
nostic and surveillance colonoscopy) and cancer treat-
ment. The uncertainty associated with the magnitude of
the follow-up costs may be a particularly important barrier
to overcome.
Secondly, such programs could include the option of
stool testing, which can be performed at home and has
lower “up-front” effort and costs required compared
with screening colonoscopy. Along these lines, Inadomi
and colleagues found that uptake of CRC screening in a
vulnerable urban population was higher when patients
were offered FOBT alone or the option of FOBT or co-
lonoscopy compared with only offering screening colo-
noscopy [25].
Our work suggests that DCE is a feasible technique
for eliciting preferences of vulnerable individuals about
potential health promotion policies. Based on prior be-
havioral economics research [26,27], we expected to see
stronger negative preferences for the modest copay-
ments and more strongly positive preferences for the
modest reward levels; the lack of such effects suggests
that the relatively small monetary copayments or re-
wards may have little effect themselves on program up-
take, at least in comparison with the extreme levels (e.g.
those associated with having to pay for screening colo-
noscopy completely out of pocket). Also, our DCE re-
sults differed somewhat from our direct question results,
with the DCE suggesting a great deal of importance at-
tached to costs whereas the direct questions also found
considerable importance attached to testing options. These
results suggest that the different techniques (DCE and
direct questions) may have complementary value [10,11].
Our findings should be considered in light of several
limitations. Foremost, we examined participants’ stated
preferences; their actual behaviors (e.g. actual partici-
pation in screening programs) may differ. Secondly, wewere only able to test a limited number of attributes and
levels while maintaining a feasible and valid survey de-
sign; including other attributes or different levels within
attributes, may have produced somewhat different re-
sults. That said, we believe that the attributes and levels
we chose are relevant and well supported in the lite-
rature. The participants’ responses about the choice of
screening tests available within the screening program
were somewhat complex and hard to interpret: they
reflected participants’ feeling about the specific tests as
well as about the value of having options. It appears par-
ticipants attached particular value to having stool testing
as one of the options, but did not necessarily value more
choice simply for the sake of having more options. More-
over, participants received brief, high-quality, evidence-
based information about the testing options, but because
we were studying preferences for screening programs, we
did not evaluate their understanding of the nuances of
each test.
We chose to represent out of pocket follow-up costs
with percentages rather than absolute amounts because
the amounts of out of pocket follow-up costs vary so
much according to whether the person always screens
negative (and hence has no additional costs), requires
diagnostic colonoscopy with or without polypectomy, or is
diagnosed with cancer and requires treatment. Given this
uncertainty, we sought to simulate how insurance pro-
grams address costs, ranging from no coverage (100% paid
by the person) to a 20% copayment, to full coverage (0%
out of pocket expense). Not surprisingly, this attribute was
considered very important, and reinforces the need for
policymakers to consider follow-up care costs when de-
signing screening programs.
Our sample size of 150 was sufficient, based on expert
opinion, to examine appropriately differentiate overall
preferences for the levels tested. However, we cannot ex-
clude that a larger sample may not be able to further
differentiate small degrees of difference in preferences.
Finally, we collected information from one (rural) region
of North Carolina; results from other parts of the state
or from other states, may differ.
Conclusions
Despite these limitations, our results suggest that pro-
grams to encourage CRC screening among vulnerable
individuals are likely to be most effective if they account
for both the direct costs of screening as well as the follow-
up costs of additional testing and treatment and if they in-
clude a stool test option. In our future work, we will use
these findings to compare the cost-effectiveness of dif-
ferent means to increase CRC screening at the state level
through organized programs, to help provide informa-
tion and guidance about efficiency as well as potential
effectiveness.
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